Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women

TABLE 1

Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

Placebo group Troglitazone group P
n 122 114
Clinical characteristics
 Age (years) 34.3 ± 6.5 34.9 ± 6.6 0.52
 BMI (kg/m2) 30.3 ± 5.3 30.6 ± 6.1 0.63
 Waist-to-hip circumference ratio 0.86 ± 0.05 0.85 ± 0.06 0.19
 Using hormonal contraceptives* 48% 43% 0.41
OGTT
 Fasting glucose (mg/dl) 98.1 ± 9.1 98.7 ± 10.2 0.64
2-h glucose 154.0 ± 24.0 154.4 ± 27.0 0.97
 Total glucose area (mg/dl × min × 10−3) 18.7 ± 2.0 18.9 ± 2.0 0.25
 Impaired glucose tolerance§ 72% 69% 0.66
 Fasting insulin (μU/ml) 16.0 ± 7.5 17.0 ± 10.8 0.82
 Total insulin area (μU/ml × min) 10,209 ± 5536 9,902 ± 6543 0.55
IVGTT
 Fasting glucose (mg/dl) 94.3 ± 10.4 94.8 ± 10.2 0.71
Kg (min−1 × 100) 1.48 ± 0.40 1.42 ± 0.39 0.23
 Fasting insulin (μU/ml) 18.7 ± 9.7 16.6 ± 9.5 0.05
Si (min−1 per μU/ml × 10−4)# 2.28 ± 1.75 2.64 ± 1.70 0.05
 AIRg (μU/ml × min)** 569 ± 527 454 ± 360 0.18
 Total insulin area (units/ml × min) 10,686 ± 5686 9,273 ± 5434 0.03
 DI (SI × AIRg)†† 983 ± 697 976 ± 717 0.99
  • Data are means ± SD. P values by two group t test for means, χ2, or Fisher’s exact test for proportions.

  • *

    * Combination oral contraceptives or depo-provera;

  • 75-g OGTT;

  • calculated by trapezoid method using data from entire duration of test;

  • §

    § plasma glucose 140–199 mg/dl 2 h after 75-g oral glucose load;

  • IVGTT, as described in research design and methods;

  • fractional glucose disappearance rate 10–40 min after glucose injection;

  • #

    # calculated by the Bergman minimal model (11);

  • **

    ** incremental insulin area 0–10 min after the glucose injection;

  • ††

    †† a measure of β-cell compensation for insulin resistance (9,14,15). To convert values for glucose to mmol/l, multiply by 0.05551. To convert values for insulin to pmol/l, multiply by 6.0.

This Article

  1. Diabetes vol. 51 no. 9 2796-2803